EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Using 18F-FDG PET/CT-derived body composition features to predict lymphovascular invasion in non-small cell lung cancer

Zewen Jiang, David Haberl, Clemens Spielvogel, Szabolcs Szakall, Peter Molnar, Josef Yu, Victor Lungu, Janos Fillinger, Ferenc Renyi-Vamos, Clemens Aigner, Balazs Dome, Christian Lang und 3 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2026-01 · 53 (2) · 774-785

DOI: 10.1007/s00259-025-07435-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 23.07.2025. Verfasst von Zewen Jiang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Währinger Gürtel 18-20, 1090, …. Hauptthemen laut MEDLINE: Fluorodeoxyglucose F18, Positron Emission Tomography Computed Tomography, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Vienna.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lymphovascular invasion (LVI) in non-small cell lung cancer (NSCLC) is a critical prognostic marker linked to higher risks of metastasis and recurrence. This study aimed to develop a non-invasive predictive model using body composition features from 18 F-FDG PET/CT imaging to assess LVI risk in early-stage NSCLC patients.

Methods

We retrospectively analyzed 248 patients, including 153 from Vienna (training cohort) and 95 from Budapest (validation cohort). Preoperative 18 F-FDG PET/CT scans were used to assess tumor metabolic parameters, including standardized uptake values (SUVmax, SUVmean), metabolic tumor volume (MTV), and total lesion glycolysis (TLG), as well as body composition features, including visceral, subcutaneous, and intermuscular adipose tissue, skeletal muscle at L1–L5. LASSO regression identified key body composition features, and a logistic regression-based nomogram was constructed and validated through ROC analysis, calibration, decision curve analysis, and survival analysis.

Results

LVI was present in 66/153 (43.1%) of Vienna and 39/95 (41.1%) of Budapest patients. The nomogram, developed using the Vienna training cohort, incorporating MTV, N stage, and body composition achieved an AUC of 0.839 and 0.790 in the Budapest validation cohort. Statistical tests confirmed that the nomogram significantly outperformed models based on either clinical ( p = 7.92e-06) or imaging variables alone ( p = 0.0474). Furthermore, LVI predicted by the nomogram was associated with significantly poorer 3-year recurrence-free and 5-year survival.

Conclusion

Integrating body composition with clinical and tumor metabolic features from PET/CT enables preoperative prediction of LVI in NSCLC, supporting improved risk stratification. Graphical abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fluorodeoxyglucose F18Positron Emission Tomography Computed TomographyCarcinoma, Non-Small-Cell LungLung NeoplasmsBody CompositionHumansMaleFemaleMiddle AgedAgedRetrospective StudiesNeoplasm InvasivenessLymphatic MetastasisAdultNomograms

Stichwörter der Autor:innen

18F-FDG PET/CTBody compositionLymphovascular invasionNSCLC

Substanzen

Fluorodeoxyglucose F18

Autor:innen und Institutionen

  • Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
  • Christian Doppler Laboratory of Applied Metabolomics, Medical University of Vienna, Vienna, Austria.
  • Pozitron PET/CT Center, Budapest, Hungary.
  • National Koranyi Institute of Pulmonology, Budapest, Hungary.
  • Department of Thoracic Surgery, National Institute of Oncology-Semmelweis University, Budapest, Hungary.
  • National Institute of Oncology and National Tumor Biology Laboratory, Budapest, Hungary.

ORCID-Profile: Marcus Hacker

Förderung

  • Medical University of Vienna

Zitieren

APA

Jiang, Z., Haberl, D., Spielvogel, C., Szakall, S., Molnar, P., Yu, J., Lungu, V., Fillinger, J., Renyi-Vamos, F., Aigner, C., Dome, B., Lang, C., Kenner, L., Megyesfalvi, Z., & Hacker, M. (2026). Using 18F-FDG PET/CT-derived body composition features to predict lymphovascular invasion in non-small cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 53(2), 774-785. https://doi.org/10.1007/s00259-025-07435-4

Vancouver

Jiang Z, Haberl D, Spielvogel C, Szakall S, Molnar P, Yu J, et al. Using 18F-FDG PET/CT-derived body composition features to predict lymphovascular invasion in non-small cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(2):774-785. doi:10.1007/s00259-025-07435-4

BibTeX
@article{Jiang2026,
  author = {Jiang, Zewen and Haberl, David and Spielvogel, Clemens and Szakall, Szabolcs and Molnar, Peter and Yu, Josef and Lungu, Victor and Fillinger, Janos and Renyi-Vamos, Ferenc and Aigner, Clemens and Dome, Balazs and Lang, Christian and Kenner, Lukas and Megyesfalvi, Zsolt and Hacker, Marcus},
  title = {Using 18F-FDG PET/CT-derived body composition features to predict lymphovascular invasion in non-small cell lung cancer},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  volume = {53},
  number = {2},
  pages = {774--785},
  doi = {10.1007/s00259-025-07435-4}
}
Kostenlos starten →